The downgrade from Positive to Neutral by a significant analyst like Susquehanna, coupled with a reduction in price target, is likely to negatively impact investor sentiment towards CTSH in the short term. This could lead to a decrease in stock price as market participants adjust their expectations based on the new analyst rating and price target.